VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18

Or Yehuda, ISRAEL

TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Andrew Brenner, MD, will present a poster on VB-111 (ofranergene obadenovec) at the 22nd Annual Society for Neuro-Oncology (SNO) Meeting, to be held November 16-19, 2017 at the Marriot Marquis in San Francisco, California.

e-Poster Presentation Details:
Title:Biomarker Analysis Supports the VB-111 Dual Mechanism of
Action and Provides a Link to its Clinical Effect on OS and PFS in
rGBM Patients 
Date:Saturday, November 18, 2017
Time:5:00 PM
e-Talk Session:Adult Therapeutics – Golden Gate C1
Poster Presentation Details:
Date:Saturday, November 18, 2017
Time: 5:00 PM – 7:00 PM Pacific Time
Session:Saturday Traditional Posters

About VB-111 (ofranergene obadenovec)
VB-111, a first-in-class anticancer therapeutic candidate, is the Company’s lead product currently being studied in a Phase 3 pivotal trial for recurrent glioblastoma multiforme (rGBM). VB-111 has demonstrated statistically significant overall survival and a progression-free survival benefit in a Phase 2 trial in patients with rGBM. VB-111 has received fast track designation in the US for prolongation of survival in patients with recurrent GBM, and orphan drug designation for treatment of GBM in both the US and Europe. VB-111 has also received an orphan designation for the treatment of ovarian cancer by the European Medicines Agency (EMA). 

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111 (ofranergene obadenovec), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. VB-111 is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding VB-111, including its clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. In particular, results from our pivotal Phase 3 clinical trial of VB-111 in rGBM may not support approval of VB-111 for marketing in the United States, notwithstanding the positive results seen in prior clinical experience. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384